These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

829 related items for PubMed ID: 9474477

  • 1. Multidrug-resistant gram-positive pathogens. An update on current microbiological patterns.
    Marchese A, Debbia EA, Bacca D, Balistreri G, Musolino B, Schito GC.
    Drugs; 1997; 54 Suppl 6():11-20. PubMed ID: 9474477
    [Abstract] [Full Text] [Related]

  • 2. European Glycopeptide Susceptibility Survey of gram-positive bacteria for 1995. European Glycopeptide Resistance Survey Study Group.
    Felmingham D, Brown DF, Soussy CJ.
    Diagn Microbiol Infect Dis; 1998 Aug; 31(4):563-71. PubMed ID: 9764397
    [Abstract] [Full Text] [Related]

  • 3. Clinical relevance of a European collaborative study on comparative susceptibility of gram-positive clinical isolates to teicoplanin and vancomycin.
    Grüneberg RN, Hryniewicz W.
    Int J Antimicrob Agents; 1998 Nov; 10(4):271-7. PubMed ID: 9916900
    [Abstract] [Full Text] [Related]

  • 4. Proficiency of Italian clinical laboratories in detecting reduced glycopeptide susceptibility in Enterococcus and Staphylococcus spp. using routine laboratory methodologies.
    Jones ME, Gesu G, Ortisi G, Sahm DF, Critchley IA, Goglio A, Associazione Microbiologi Clinici Italiani (AMCLI) Committee for Antibiotics.
    Clin Microbiol Infect; 2002 Feb; 8(2):101-11. PubMed ID: 11952723
    [Abstract] [Full Text] [Related]

  • 5. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
    Biedenbach DJ, Bell JM, Sader HS, Fritsche TR, Jones RN, Turnidge JD.
    Int J Antimicrob Agents; 2007 Aug; 30(2):143-9. PubMed ID: 17531446
    [Abstract] [Full Text] [Related]

  • 6. Resistance of enterococci to ampicillin and glycopeptide antibiotics in Italy. The Italian Surveillance Group for Antimicrobial Resistance.
    Fontana R, Ligozzi M, Mazzariol A, Veneri G, Cornaglia G.
    Clin Infect Dis; 1998 Aug; 27 Suppl 1():S84-6. PubMed ID: 9710675
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. In vitro susceptibility of Staphylococci and Enterococci to vancomycin and teicoplanin.
    Guzek A, Korzeniewski K, Nitsch-Osuch A, Rybicki Z, Prokop E.
    Adv Exp Med Biol; 2013 Aug; 788():125-32. PubMed ID: 23835969
    [Abstract] [Full Text] [Related]

  • 10. Enterococci and vancomycin resistance.
    French GL.
    Clin Infect Dis; 1998 Aug; 27 Suppl 1():S75-83. PubMed ID: 9710674
    [Abstract] [Full Text] [Related]

  • 11. In vitro activity of oritavancin and comparator agents against staphylococci, streptococci and enterococci from clinical infections in Europe and North America, 2011-2014.
    Biedenbach DJ, Arhin FF, Moeck G, Lynch TF, Sahm DF.
    Int J Antimicrob Agents; 2015 Dec; 46(6):674-81. PubMed ID: 26541881
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Activities of the semisynthetic glycopeptide LY191145 against vancomycin-resistant enterococci and other gram-positive bacteria.
    Nicas TI, Mullen DL, Flokowitsch JE, Preston DA, Snyder NJ, Stratford RE, Cooper RD.
    Antimicrob Agents Chemother; 1995 Nov; 39(11):2585-7. PubMed ID: 8585753
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Glycopeptide tolerance in bacteria causing endocarditis.
    Perry JD, Jones AL, Gould FK.
    J Antimicrob Chemother; 1999 Jul; 44(1):121-4. PubMed ID: 10459820
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Semisynthetic glycopeptide antibiotics derived from LY264826 active against vancomycin-resistant enterococci.
    Nicas TI, Mullen DL, Flokowitsch JE, Preston DA, Snyder NJ, Zweifel MJ, Wilkie SC, Rodriguez MJ, Thompson RC, Cooper RD.
    Antimicrob Agents Chemother; 1996 Sep; 40(9):2194-9. PubMed ID: 8878606
    [Abstract] [Full Text] [Related]

  • 18. Quality assessment of glycopeptide susceptibility tests: a European collaborative study. European Glycopeptide Resistance Group.
    Brown DF, Courvalin P.
    Int J Antimicrob Agents; 1997 Jan; 9(3):153-63. PubMed ID: 9552711
    [Abstract] [Full Text] [Related]

  • 19. Activity of dalbavancin and comparator agents against Gram-positive cocci from clinical infections in the USA and Europe 2015-16.
    Pfaller MA, Mendes RE, Duncan LR, Flamm RK, Sader HS.
    J Antimicrob Chemother; 2018 Oct 01; 73(10):2748-2756. PubMed ID: 29982565
    [Abstract] [Full Text] [Related]

  • 20. [In vitro activity of vancomycin and teicoplanin against gram-positive cocci].
    Bezian MC, Ribou G, Masquelier B.
    Pathol Biol (Paris); 1992 May 01; 40(5):461-5. PubMed ID: 1386667
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.